Literature DB >> 33853960

An H1N1 Computationally Optimized Broadly Reactive Antigen Elicits a Neutralizing Antibody Response against an Emerging Human-Infecting Eurasian Avian-Like Swine Influenza Virus.

Giuseppe A Sautto1, Jeffrey W Ecker1, Ted M Ross1,2.   

Abstract

Entities:  

Keywords:  H1N1; hemagglutinin; influenza; vaccine

Mesh：

Substances：

Year:  2021        PMID： 33853960      PMCID： PMC8316128          DOI： 10.1128/JVI.02421-20

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  10 in total

1.  Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection.

Authors:  Honglei Sun; Yihong Xiao; Jiyu Liu; Dayan Wang; Fangtao Li; Chenxi Wang; Chong Li; Junda Zhu; Jingwei Song; Haoran Sun; Zhimin Jiang; Litao Liu; Xin Zhang; Kai Wei; Dongjun Hou; Juan Pu; Yipeng Sun; Qi Tong; Yuhai Bi; Kin-Chow Chang; Sidang Liu; George F Gao; Jinhua Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

2.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Elicitation of Broadly Protective Antibodies following Infection with Influenza Viruses Expressing H1N1 Computationally Optimized Broadly Reactive Hemagglutinin Antigens.

Authors:  Giuseppe A Sautto; Greg A Kirchenbaum; Jeffrey W Ecker; Anne-Gaelle Bebin-Blackwell; Spencer R Pierce; Ted M Ross
Journal:  Immunohorizons       Date:  2018-08-27

4.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

5.  An Influenza Virus Hemagglutinin Computationally Optimized Broadly Reactive Antigen Elicits Antibodies Endowed with Group 1 Heterosubtypic Breadth against Swine Influenza Viruses.

Authors:  Amanda L Skarlupka; Z Beau Reneer; Rodrigo B Abreu; Ted M Ross; Giuseppe A Sautto
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

6.  A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.

Authors:  Giuseppe A Sautto; Greg A Kirchenbaum; Rodrigo B Abreu; Jeffrey W Ecker; Spencer R Pierce; Harry Kleanthous; Ted M Ross
Journal:  J Immunol       Date:  2019-12-06       Impact factor: 5.422

7.  A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Authors:  Brendan M Giles; Ted M Ross
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

8.  Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.

Authors:  Terianne M Wong; James D Allen; Anne-Gaelle Bebin-Blackwell; Donald M Carter; Timothy Alefantis; Joshua DiNapoli; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 9.  Towards a universal influenza vaccine: different approaches for one goal.

Authors:  Giuseppe A Sautto; Greg A Kirchenbaum; Ted M Ross
Journal:  Virol J       Date:  2018-01-19       Impact factor: 4.099
  10 in total
  1 in total

1.  A Competitive Hemagglutination Inhibition Assay for Dissecting Functional Antibody Activity against Influenza Virus.

Authors:  Greg A Kirchenbaum; Giuseppe A Sautto; Robert A Richardson; Jeffrey W Ecker; Ted M Ross
Journal:  J Virol       Date:  2021-09-15       Impact factor: 5.103
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.